ClinicalTrials HQ

A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

Active, not recruiting · NCT06525220 · Registry updated 2026-09-25
Ask about research services

Clinical trials

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, laryngeal disorder, neoplasm, otorhinolaryngologic disease, respiratory system disorder, squamous cell carcinomaActive, not recruitingPhase 32026-09-25NCT06525220

1 results · Page 1 of 1

Organizations

Swipe the table sideways for more columns.

OrganizationsLinked trials
Merus B.V.4

202 results · Page 1 of 9

Research sites

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
Site 1HoustonUnited States1
Site 10Salt Lake CityUnited States1
Site 100DresdenGermany1
Site 101Le MansFrance1
Site 102CambridgeUnited Kingdom1
Site 103Kaohsiung CityTaiwan1
Site 104HanoverGermany1
Site 105ParisFrance1
Site 106GliwicePoland1
Site 107Pathum WanThailand1
Site 108Washington D.C.United States1
Site 109LiègeBelgium1
Site 11BlacktownAustralia1
Site 110WürzburgGermany1
Site 111WinnipegCanada1
Site 112VillejuifFrance1
Site 113DurhamUnited States1
Site 114Bangkok NoiThailand1
Site 115MemphisUnited States1
Site 116KrakowPoland1
Site 117HeraklionGreece1
Site 118Winston-SalemUnited States1
Site 119PátraiGreece1
Site 12BlacksburgUnited States1
Site 120BadalonaSpain1